
News|Podcasts|December 19, 2024
Mastering Antibody-Drug Conjugates
Author(s)BIOVECTRA
In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet
2
Conjugation and Regulation Challenges for Advanced Molecules: Part Two of Three with Abzena
3
Top BP Videos of 2025: An Intersection of AI, Innovation, and Compliance
4
FAQ: Understanding Biosimilars, Biobetters, and Interchangeability
5




